Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Launched by UNIVERSITY HOSPITAL, GHENT · Apr 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of psilocybin, a naturally occurring compound found in certain mushrooms, to help patients hospitalized for treatment-resistant depression. The goal is to see if combining psilocybin with therapy can be both safe and effective for people who have not responded to traditional antidepressant medications. Participants in the study must be at least 18 years old and have a diagnosis of major depressive disorder that has not improved even after trying two or more different antidepressant treatments. They should be stable health-wise and not have certain other mental health conditions or serious medical issues.

If you or a loved one are eligible and decide to participate, you will receive psilocybin in a controlled environment, along with psychotherapy sessions. The study is actively recruiting participants, and it’s important to note that women who can become pregnant must use reliable birth control during the trial. This research could provide new insights into treating depression, especially for those who feel they have run out of options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older.
• • 2. Diagnosis of major depressive disorder (single and recurrent episodes) of moderate to severe degree (MADRS score ≥ 20) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), without psychotic features. Included ICD-11 diagnoses are ICD-11: 6A70.1, 6A70.3, 6A71.1, 6A71.3.
• • 3. Subjects have failed to respond to 2 or more antidepressants prescribed at the minimum effective dose for at least 6 weeks. Augmentation with an add-on treatment counts as a second treatment.
• • 4. The subjects are abstinent from alcohol (breathalyzer blood alcohol concentration (BAC) level 0.00) and provide a negative urine drug screen at the dosing day.
• • 5. The female subjects provide a negative pregnancy test at the dosing day.
• • 6. The subjects must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead ECG performed at screening.
• • - In 12-lead ECG, QTcF should be ≤ 450 ms for males or ≤ 470 ms for females and PR-interval \< 220 ms at screening.
• • 7. A partner is willing to participate in the study (a cohabiting relationship of at least 1 year).
• Exclusion Criteria:
• • 1. Currently comorbid or previously diagnosed DSM-5 diagnosis of a
• • 1. major depressive episode with psychotic features.
• • 2. psychotic disorder (defined as meeting DSM-5 criteria for any psychotic disorder) on the MINI 7.0, EXCEPT substance/medication induced psychotic disorder where the duration was limited to the acute period of direct intoxication with the substance/medication. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
• • 3. bipolar disorder (defined as meeting DSM-5 criteria for bipolar type 1 or bipolar type 2) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
• • 4. drug or alcohol dependence syndrome (defined as meeting DSM-5 criteria for any dependence syndrome) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
• • 5. cluster B personality disorder. Subjects will be screened for the presence of those personality traits by using the NEO-FFI-3.
• • 6. PTSD (defined as meeting DSM-5 criteria for PTSD) on the MINI 7.0. Positive diagnoses on the MINI will be subject to confirmation at clinical interview by a psychiatrist.
• • 2. A family history (first-degree relative) of psychosis and/or bipolar disorder.
• • 3. Current active suicidal ideations.
• • 4. Depression secondary to other medical conditions.
• 5. Medical diagnosis incompatible with psilocybin treatment:
• • 1. Cardiovascular conditions: recent stroke (\< 1 year from signing of ICF), recent myocardial infarction (\< 1 year from signing of ICF), uncontrolled hypertension (blood pressure \> 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.
• • 2. Uncontrolled insulin-dependent diabetes mellitus.
• • 3. Uncontrolled epilepsy.
• • 6. Biochemical or electrocardiographic abnormalities determined as clinically significant by a medical doctor. PsiHos-D, Version 2.1 dd. 22/02/2024 page 59 of 114 TMP_Protocol AGO CTR_Version 1.0_Effective Date 2022-07-18
• • 7. Current intake of Lithium, Disulfiram, MAOIs or inhibitors of UGT1A9 and 1A10.
• • 8. The subject has received any prior treatment with vagal nerve stimulation, or a deep brain stimulation device.
• • 9. Women of childbearing potential not using adequate contraception (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
• • 10. Pregnant or breast-feeding women.
• • 11. Those unable to give informed consent.
• • 12. Those enrolled in another trial.